International Journal of Clinical Case Reports 2024, Vol.14, No.4, 202-209 http://medscipublisher.com/index.php/ijccr 209 Nguyen D., Yang W., Renganathan A., Weimholt C., Angappulige D.H., Nguyen T., Patel A.K., Agarwal N., Teer J., Coppola D., Zhang J., Perera R., and Mahajan K., 2022, Acetylated HOXB13 regulated super enhancer genes define therapeutic vulnerabilities of castration-resistant prostate cancer, Clinical Cancer Research, 28(18): 4131-4145. https://doi.org/10.1158/1078-0432.CCR-21-3603 PMID: 35849143 PMCID: PMC9481728 Park C., Shin S.J., Cho Y., Joo J.W., and Cho N., 2019, HOXB13 expression in ductal type adenocarcinoma of prostate: clinicopathologic characteristics and its utility as potential diagnostic marker, Scientific Reports, 9(1): 20205. https://doi.org/10.1038/s41598-019-56657-8 PMID: 31882852 PMCID: PMC6934792 Patel R.A., Sayar E., Coleman I.M., Roudier M.P., Hanratty B., Low J., Jaiswal N., Ajkunic A., Dumpit R., and Ercan C., 2023, Characterization of HOXB13 expression patterns in localized and metastatic castration‐resistant prostate cancer, The Journal of Pathology, 262. https://doi.org/10.1002/path.6216 PMID: 37850574 PMCID: PMC10871027 Schnoeller T., Luedeke M., Rinckleb A., Stanford J., FitzGerald L., Schleutker J., Wahlfors T., Eeles R., Kote-Jarai Z., Weikert S., Krause H., Herkommer K., and Maier C., 2015, Association of the prostate cancer risk mutation G84E in HOXB13 with the subtype of ETS fusion negative adenocarcinoma with early age of diagnosis, Journal of Clinical Oncology, 33(15): 5021. https://doi.org/10.1200/JCO.2015.33.15_SUPPL.5021 Sharp A., Coleman I.M., Yuan W., Sprenger C., Dolling D., Rodrigues D., Russo J.W., Figueiredo I., Bertan C., Seed G., Riisnaes R., Uo T., Neeb A., Welti J., Morrissey C., Luo J., Nelson P., Balk S., True L., de Bono J.D., and Plymate S., 2018, Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer, Journal of Clinical Investigation, 129(1): 192-208. https://doi.org/10.1172/JCI122819 PMID: 30334814 PMCID: PMC6307949 Sipeky C., Gao P., Zhang Q., Wang L., Ettala O., Talala K., Tammela T., Auvinen A., Wiklund F., and Schleutker J., 2018, Synergistic interaction of HOXB13 and CIP2Apredisposes to aggressive prostate cancer, Clinical Cancer Research, 24: 6265-6276. https://doi.org/10.1158/1078-0432.CCR-18-0444 Song R.S., Sun K., Wang Y.X., Liu S.K., and Bu Y.Y., 2024, Synthetic microbial communities: redesigning genetic pathways for enhanced functional synergy, Molecular Microbiology Research, 14(1): 39-48. https://doi.org/10.5376/mmr.2024.14.0005 Tilki D., Schaeffer E., and Evans C., 2016, Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor, European Urology Focus, 2(5): 499-505. https://doi.org/10.1016/j.euf.2016.11.013 PMID: 28723515 Wang T., 2024, The application prospects of immunomodulators in cancer treatment, Cancer Genetics and Epigenetics, 12(1): 1-7. https://doi.org/10.5376/cge.2024.12.0001 Weiner A., Faisal F.A., Davicioni E., Karnes R.J., Vander Griend D.J., Lotan T., and Schaeffer E., 2020, Somatic HOXB13 expression correlates with metastatic progression in men with localized prostate cancer following radical prostatectomy, European Urology Oncology, 4(6): 955-962. https://doi.org/10.1016/j.euo.2020.05.001 PMID: 32540218 PMCID: PMC7736205 Yao J., Chen Y., Nguyen D., Thompson Z., Eroshkin A., Nerlakanti N., Patel A.K., Agarwal N., Teer J., Dhillon J., Coppola D., Zhang J., Perera R., and Mahajan K., 2019, The Homeobox gene, HOXB13, regulates a mitotic protein-kinase interaction network in metastatic prostate cancers, Scientific Reports, 9: Article 46064. https://doi.org/10.1038/s41598-019-46064-4 PMID: 31273254 PMCID: PMC6609629 Zabalza C.V., Adam M., Burdelski C., Wilczak W., Wittmer C., Kraft S., Krech T., Steurer S., Koop C., and Hube-Magg C., 2015, HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy, Oncotarget, 6: 12822-12834. https://doi.org/10.18632/oncotarget.3431 PMID: 25825985 PMCID: PMC4494977
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==